KX2-391 Dihydrochloride: Dual Src Kinase and Tubulin Inhibitor for Precision Cancer and Antiviral Research

Executive Summary: KX2-391 dihydrochloride (SKU A3535, also known as Tirbanibulin dihydrochloride) is a small-molecule inhibitor with dual activity against Src kinase and tubulin polymerization, validated in both cellular and in vivo models (Koc et al., 2024; APExBIO). Inhibition of Src kinase occurs at nanomolar concentrations (IC50 = 23–39 nM in engineered NIH3T3 and SYF cell lines), while tubulin polymerization is disrupted at ≥80 nM. The compound effectively suppresses hepatitis B virus (HBV) transcription and inhibits botulinum neurotoxin A (BoNT/A) activity by directly targeting the BoNT/A light chain, with documented efficacy in pre- and post-intoxication models. KX2-391 is orally bioavailable and clinically validated for topical treatment of actinic keratosis. These attributes make it a versatile research tool across oncology, virology, and neurotoxin studies.

Biological Rationale

Src family kinases are non-receptor tyrosine kinases implicated in cancer cell proliferation, migration, and survival. Abnormal Src signaling is a hallmark in multiple malignancies (APExBIO). Tubulin polymerization is essential for mitotic spindle formation, and its inhibition disrupts cell division. A compound that targets both Src kinase and the cytoskeleton offers a synergistic strategy to impair tumor growth and metastasis. Recent research also reveals that KX2-391 suppresses HBV replication by interfering with viral transcription, and blocks BoNT/A neurotoxin activity by targeting the SNAP-25 cleavage mechanism (Koc et al., 2024).

Mechanism of Action of KX2-391 dihydrochloride

• Src Kinase Inhibition: KX2-391 binds the substrate-binding site of Src kinase, with IC50 values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F), effectively blocking downstream signaling involved in proliferation and survival.
• Tubulin Polymerization Inhibition: The molecule binds a novel site on the α-β tubulin heterodimer, disrupting polymerization at ≥80 nM and leading to cytoskeletal destabilization and mitotic arrest.
• HBV Transcription Suppression: KX2-391 inhibits HBV precore promoter activity, reducing viral mRNA with EC50 values of 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells.
• BoNT/A Inhibition: The compound blocks cleavage of SNAP-25 by BoNT/A light chain at 10–40 μM, impeding neurotoxin activity in both pre- and post-intoxication models (Koc et al., 2024).

Evidence & Benchmarks

• KX2-391 inhibits Src kinase activity with IC50 values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) in vitro (APExBIO).
• Tubulin polymerization is blocked in cellular assays at ≥80 nM, leading to mitotic arrest (APExBIO).
• HBV transcription is suppressed with EC50 = 0.14 μM (PXB cells) and 2.7 μM (HepG2-NTCP cells), confirming antiviral efficacy (APExBIO).
• KX2-391 blocks BoNT/A-mediated SNAP-25 cleavage at 10–40 μM in neuronal models, demonstrating both pre- and post-intoxication efficacy (DOI:10.1002/ddr.22248).
• Oral administration in mice at 5–15 mg/kg (once or twice daily) and in chimpanzees at 1 mg/kg (twice daily) achieves systemic exposure for anti-HBV studies (APExBIO).
• Topical 1% ointment achieves clinical efficacy in actinic keratosis without significant peripheral neuropathy (APExBIO).

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is validated for use in cancer research, HBV replication studies, and BoNT/A neurotoxin inhibition. Its dual mechanism enables precise dissection of Src and tubulin pathways in oncogenic and antiviral models. The compound is also utilized in studies of caspase and Src kinase signaling, as well as cytoskeletal dynamics. For a detailed workflow-based Q&A and experimental troubleshooting, see this scenario-driven solution guide, which this article extends by adding peer-reviewed antiviral and neurotoxin data.

In contrast to recent reviews of assay reliability, this dossier directly benchmarks KX2-391 using current in vivo and antiviral models, clarifying its spectrum of validated applications and pharmacological boundaries.

Common Pitfalls or Misconceptions

• Water Solubility: KX2-391 dihydrochloride is insoluble in water; DMSO (≥25.2 mg/mL) or ethanol (≥48.8 mg/mL, with warming) are required for stock solutions (APExBIO).
• Non-selectivity at High Concentrations: Above 40 μM, off-target effects may confound interpretation—concentration optimization is essential (Koc et al., 2024).
• Not a Universal BoNT Inhibitor: Efficacy is established for BoNT/A, but not for all botulinum neurotoxin serotypes (Koc et al., 2024).
• Clinical Use Limitations: Approved only as a 1% topical ointment for actinic keratosis; oral or systemic use is investigational and dose-dependent (APExBIO).
• Not a Broad-Spectrum Antiviral: Antiviral activity is validated for HBV only, with no evidence for efficacy against other viruses (APExBIO).

Workflow Integration & Parameters

• In Vitro Concentrations: Range from 0.013 to 10 μM in anticancer and anti-HBV assays; 10–40 μM for BoNT/A inhibition (APExBIO).
• In Vivo Dosing: Oral administration in mice (5–15 mg/kg, once or twice daily) and chimpanzees (1 mg/kg, twice daily) for anti-HBV studies.
• Formulation: Supplied as a solid; store at -20°C. Dissolve in DMSO or ethanol with gentle warming.
• Clinical Regimens: 1% ointment for actinic keratosis; oral doses of 40–120 mg/day in tumor studies (APExBIO).
• Data Integrity: For optimizing assay reproducibility with KX2-391, refer to assay reliability guidelines; this article builds on those by adding dual-pathway and antiviral benchmarks.

Conclusion & Outlook

KX2-391 dihydrochloride, available from APExBIO, is a validated, dual mechanism Src kinase and tubulin polymerization inhibitor with robust evidence for anticancer, anti-HBV, and anti-BoNT/A activity. Its precise molecular targeting, documented pharmacokinetics, and clinical tolerability make it a valuable research reagent for dissecting oncogenic, cytoskeletal, and antiviral pathways. Future studies may extend its application to additional viral and neurotoxin models, but current data support its use as a reliable, high-integrity tool for translational research. For product specifications and ordering, visit the KX2-391 dihydrochloride product page.